Payment overview · 2025
General Payments
$226.76
14 reported records · 9 companies
Healthcare provider profile · identity verified
Melissa E Manhart, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WASHINGTON, MO · NPI 1679786990
Verified facts
What the public records show
CMS Open Payments records show Melissa E Manhart, NP received $226.76 in general payments during 2025 across 14 reported records.
Abbott Laboratories accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.69 | 29.4% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.84 | 14.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.65 | 13.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.68 | 8.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.06 | 7.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.85 | 7.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.29 | 6.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.87 | 6.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.83 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $226.76 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.69 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $44.48 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $33.84 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 187 | 64 |
| Lisinopril | Lisinopril | 108 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 88 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 29 |
| Losartan Potassium | Losartan Potassium | 78 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 17 |
| Omeprazole | Omeprazole | 55 | 23 |
| Metformin Hcl Er | Metformin Hcl | 53 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 20 |
| Meloxicam | Meloxicam | 48 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 20 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Simvastatin | Simvastatin | 44 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 13 |
| Gabapentin | Gabapentin | 42 | 14 |
| Metformin Hcl | Metformin Hcl | 42 | 15 |
| Furosemide | Furosemide | 40 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Eliquis | Apixaban | 34 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 30 | 13 |
| Alendronate Sodium | Alendronate Sodium | 28 | 11 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 27 | 27 |
| Cephalexin | Cephalexin | 27 | 27 |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 15 | 12 |
| Allopurinol | Allopurinol | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Finasteride | Finasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.76 · 14 records | Abbott Laboratories | Auvelity, FREESTYLE LIBRE 3, REXULTI, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error